The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment

被引：0
|
作者：
Jin, Shanshan
Zhang, Xiaochen
Jia, Yunlu
Dai, Yongchao
Xu, Fengwei
Huang, Yongfeng
Wang, Xun
Wu, Hailong
Shao, Yu
Long, Jinfeng
Zheng, Anjie
Xu, Yuhong
机构：
[1] Hangzhou HighField Biopharmaceut Corp, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[3] Zhejiang Univ, Sch Pharm, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3035
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine
    Disis, M. L.
    Salazar, L. G.
    Coveler, A.
    Waisman, J.
    Higgins, D.
    Childs, J.
    Bates, N.
    Dang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab.
    Webster, D. J.
    Waisman, J.
    Macleod, B.
    Dela Rosa, C.
    Higgins, D.
    Fintak, P.
    Childs, J.
    Slota, M.
    Salazar, L. G.
    Disis, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 107S - 107S
  • [3] First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
    Guo, Y.
    Xue, J.
    Peng, W.
    Xue, L.
    Ge, X.
    Zhao, W.
    Tang, W.
    Nian, W.
    Li, Q.
    Zhang, S.
    Sun, J.
    Li, M.
    Hausheer, F.
    Hu, C.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S480 - S481
  • [4] A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
    Ku, G.
    Bendell, J. C.
    Tolcher, A. W.
    Hurvitz, S. A.
    Krishnamurthy, A.
    El-Khoueiry, A. B.
    Patnaik, A.
    Shroff, R. T.
    Noonan, A.
    Hahn, N. M.
    Matrana, M.
    Zettl, M.
    Aviano, K.
    Mar, L.
    Jolicoeur, P.
    Olwill, S.
    Bruns, I.
    Piha-Paul, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S462 - S463
  • [5] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    Yoh, K.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422
  • [6] Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors
    Wang, Jiayu
    Wang, Wenna
    Tong, Zhongsheng
    Shi, Yehui
    Shi, Yanxia
    Zheng, Qiufan
    Yu, Shunjiang
    Cao, Yuanyuan
    Xie, Ning
    Fan, Jianru
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients
    Jagtap, Deepa Bai
    Thakur, Archana
    Deol, Abhinav
    Al-Kadhimi, Zaid
    Simon, Michael S.
    Flaherty, Lawrence E.
    Shields, Anthony Frank
    Schalk, Dana
    Paul, Elyse
    Kondadasula, Vidya
    Liu, Qin
    Lum, Lawrence G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] A PHASE 1 DOSE ESCALATION STUDY OF PRS-343, A HER2/4-1BB BISPECIFIC MOLECULE, IN PATIENTS WITH HER2-POSITIVE MALIGNANCIES
    Piha-Paul, Sarina
    Bendell, Johanna
    Tolcher, Anthony
    Hurvitz, Sara
    Patnaik, Amita
    Shroff, Rachna
    Pohlmann, Paula
    Zettl, Markus
    Hahn, Noah
    Krishnamurthy, Anuradha
    Duerr, Manuela
    Mei, Jian
    Aviano, Kayti
    Yusuf, Rushdia
    Matis, Louis
    Olwill, Shane
    Bruns, Ingmar
    Ku, Geoffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A1 - A2
  • [9] Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/II HER2+ breast cancer.
    Limentani, S
    Dorval, T
    White, S
    Curigliano, G
    Campone, M
    Disis, N
    Piccart, M
    Cheever, M
    Gérard, C
    Brichard, VG
    Gauducheau, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 170S - 170S
  • [10] Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
    Osumi, H.
    Wakatsuki, T.
    Yamamoto, N.
    Ooki, A.
    Chin, K.
    Shoji, H.
    Ogura, M.
    Nakayama, I.
    Hirano, H.
    Hara, H.
    Minashi, K.
    Shinozaki, E.
    Kato, K.
    Kitano, S.
    Takeuchi, K.
    Boku, N.
    Yamaguchi, K.
    Takahari, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S897 - S897
12345